Sickle Cell Disease
Welcome,         Profile    Billing    Logout  
 40 Companies   48 Products   48 Products   0 Mechanisms of Action   20 Trials   419 News 


12345678»
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  SOMMEDREP: Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children (clinicaltrials.gov) -  Mar 13, 2019   
    P=N/A,  N=62, Completed, 
    Completed --> Terminated; Initiation of CMS BMT study for sickle-cell disease operating under NCT01166009 made further accrual to this study impossible. Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Aug 2018 | Trial primary completion date: Jan 2019 --> Aug 2018
  • ||||||||||  Trial completion date, Trial primary completion date:  SOMMEDREP: Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children (clinicaltrials.gov) -  Dec 21, 2018   
    P=N/A,  N=62, Active, not recruiting, 
    Active, not recruiting --> Completed Trial completion date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2018 --> Jan 2019
  • ||||||||||  Enrollment change, Trial completion date, Trial primary completion date:  Bi-Level Positive Airway Ventilation for Acute Chest Syndrome (clinicaltrials.gov) -  Dec 11, 2018   
    P=N/A,  N=3, Terminated, 
    Trial completion date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2018 --> Jan 2019 N=60 --> 3 | Trial completion date: Jul 2014 --> Sep 2016 | Trial primary completion date: Jul 2014 --> Sep 2016
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment change, Trial withdrawal:  Study of Beet Juice for Patients With Sickle Cell Anemia (clinicaltrials.gov) -  Aug 2, 2018   
    P2,  N=0, Withdrawn, 
    Terminated --> Completed N=24 --> 0 | Suspended --> Withdrawn
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Pain Management in Children and Young Adults With Sickle Cell Disease (clinicaltrials.gov) -  Jul 6, 2018   
    P2,  N=90, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=190 --> 90 | Trial completion date: May 2018 --> Jan 2018 | Trial primary completion date: May 2018 --> Jan 2018
  • ||||||||||  Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
    Enrollment change, Trial withdrawal:  Safety and Pharmacokinetics of SANGUINATE (clinicaltrials.gov) -  Jun 2, 2018   
    P1,  N=0, Withdrawn, 
    Recruiting --> Completed | N=190 --> 90 | Trial completion date: May 2018 --> Jan 2018 | Trial primary completion date: May 2018 --> Jan 2018 N=15 --> 0 | Suspended --> Withdrawn
  • ||||||||||  montelukast / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (clinicaltrials.gov) -  Apr 3, 2018   
    P2,  N=46, Completed, 
    N=15 --> 0 | Suspended --> Withdrawn Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Mar 2018 | Trial primary completion date: Oct 2018 --> Mar 2018
  • ||||||||||  montelukast / Generic mfg.
    Enrollment closed:  Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (clinicaltrials.gov) -  Mar 26, 2018   
    P2,  N=63, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Mar 2018 | Trial primary completion date: Oct 2018 --> Mar 2018 Recruiting --> Active, not recruiting
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion:  A Phase II Trial of Regadenoson in Sickle Cell Anemia (clinicaltrials.gov) -  Feb 7, 2018   
    P2,  N=100, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2017 --> May 2017 Recruiting --> Completed
  • ||||||||||  Trial completion date, Trial primary completion date:  Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease (clinicaltrials.gov) -  Feb 6, 2018   
    P1,  N=15, Recruiting, 
    Recruiting --> Completed Trial primary completion date: Jun 2017 --> Jun 2020 | Trial completion date: Jun 2017 --> Jun 2020
  • ||||||||||  hydroxyurea / Generic mfg.
    Phase classification, Adherence:  Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT (clinicaltrials.gov) -  Dec 2, 2017   
    P=N/A,  N=60, Completed, 
    Recruiting --> Completed | Trial primary completion date: Apr 2018 --> Apr 2017 Phase classification: P2 --> P=N/A
  • ||||||||||  hydroxyurea / Generic mfg.
    Enrollment change, Trial withdrawal:  Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study (clinicaltrials.gov) -  Oct 17, 2017   
    P2,  N=0, Withdrawn, 
    Trial primary completion date: Apr 2018 --> Sep 2018 N=10 --> 0 | Terminated --> Withdrawn
  • ||||||||||  montelukast / Generic mfg.
    Trial primary completion date:  Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (clinicaltrials.gov) -  Aug 17, 2017   
    P2,  N=63, Recruiting, 
    No longer recruiting --> Completed Trial primary completion date: Oct 2017 --> Oct 2018
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Trial termination:  Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease (clinicaltrials.gov) -  Jul 21, 2017   
    P2,  N=5, Terminated, 
    Trial primary completion date: Oct 2017 --> Oct 2018 Completed --> Terminated; The study terminated early due to slow accrual.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Heart Disease in Sickle Cell Anemia (clinicaltrials.gov) -  Jun 30, 2017   
    P=N/A,  N=120, Completed, 
    Completed --> Terminated; The study terminated early due to slow accrual. Recruiting --> Completed
  • ||||||||||  propranolol ER / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date:  Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease (clinicaltrials.gov) -  Jun 8, 2017   
    P1,  N=9, Terminated, 
    Recruiting --> Completed N=20 --> 9 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2012; Inability to recruit patients into the study.
  • ||||||||||  Amevive (alefacept) / Astellas
    Trial termination:  Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) -  Jun 7, 2017   
    P=N/A,  N=3, Terminated, 
    N=20 --> 9 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2012; Inability to recruit patients into the study. Suspended --> Terminated; drug company is no longer making the drug
  • ||||||||||  Trial completion, Trial primary completion date:  Use of Mobile Technology for Intensive Training in Medication Management (clinicaltrials.gov) -  May 25, 2017   
    P=N/A,  N=46, Completed, 
    Suspended --> Terminated; drug company is no longer making the drug Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2016
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial completion, Enrollment change, Trial primary completion date:  Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease (clinicaltrials.gov) -  May 15, 2017   
    P2,  N=22, Completed, 
    Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2016 Active, not recruiting --> Completed | N=15 --> 22 | Trial primary completion date: Dec 2017 --> Jun 2016
  • ||||||||||  Trial completion, HEOR:  Decision Aid for Therapeutic Options In Sickle Cell Disease (clinicaltrials.gov) -  Apr 21, 2017   
    P=N/A,  N=120, Completed, 
    Active, not recruiting --> Completed | N=15 --> 22 | Trial primary completion date: Dec 2017 --> Jun 2016 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Trial primary completion date:  Molecular Phenotyping of Asthma in Sickle Cell Disease (clinicaltrials.gov) -  Mar 28, 2017   
    P=N/A,  N=99, Completed, 
    Trial primary completion date: Feb 2017 --> Nov 2017 Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Feb 2016
  • ||||||||||  Trial primary completion date:  Study of Beet Juice for Patients With Sickle Cell Anemia (clinicaltrials.gov) -  Mar 8, 2017   
    P2,  N=24, Suspended, 
    Active, not recruiting --> Completed | N=40 --> 74 Trial primary completion date: Feb 2017 --> Feb 2019
  • ||||||||||  losartan / Generic mfg.
    Trial completion, Phase classification, Enrollment change:  Losartan for Sickle Cell Kidney Disease (clinicaltrials.gov) -  Feb 17, 2017   
    P,  N=24, Completed, 
    Trial primary completion date: Feb 2017 --> Feb 2019 Active, not recruiting --> Completed | Phase classification: PN/A --> P | N=40 --> 24
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Enrollment change, Trial termination, Trial primary completion date:  A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease (clinicaltrials.gov) -  Feb 3, 2017   
    P2,  N=4, Terminated, 
    Active, not recruiting --> Completed | N=30 --> 36 N=25 --> 4 | Suspended --> Terminated | Trial primary completion date: Jan 2016 --> Jan 2015; PI moving to a different institution.
  • ||||||||||  Trial primary completion date, HEOR:  Decision Aid for Therapeutic Options In Sickle Cell Disease (clinicaltrials.gov) -  Feb 1, 2017   
    P=N/A,  N=120, Active, not recruiting, 
    N=25 --> 4 | Suspended --> Terminated | Trial primary completion date: Jan 2016 --> Jan 2015; PI moving to a different institution. Trial primary completion date: Dec 2016 --> Jul 2017
  • ||||||||||  fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
    Trial completion, Enrollment change:  Sickle Cell Disease Conditioning for Bone Marrow Transplant (clinicaltrials.gov) -  Jan 26, 2017   
    P1,  N=8, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> May 2018 Suspended --> Completed | N=24 --> 8
  • ||||||||||  Enrollment change, Trial withdrawal, Trial primary completion date:  Androgen Regulation of Priapism in Sickle Cell Disease (clinicaltrials.gov) -  Jan 19, 2017   
    P=N/A,  N=0, Withdrawn, 
    Suspended --> Completed | N=24 --> 8 N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2017 --> Jan 2016